Download Presentation

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Chemotherapy-Induced
Cardiomyopathy
Monica Abraham
Intern Mentor
Atholton High School
Mentor:
Lili Barouch, M.D.
Johns Hopkins Cardiology
Columbia Medical Campus
Preview
•
•
•
•
•
•
Research Question
Anthracyclines
Chemotherapy-Induced Cardiomyopathy
Risk Factors
My Research
Conclusion
Research Question
• Which risk factor makes patients most likely to
develop chemotherapy-induced cardiomyopathy?
Research Design: Causal-Comparative
• Terms:
-chemotherapy: the treatment of cancer by the
use of chemical substances
-cardiomyopathy: the deterioration of the heart
muscle
-anthracycline: common type of breast cancer
chemotherapy drug
-myocyte: muscle cell
Anthracyclines
• Chemotherapy agents
• Commonly treat breast
cancer and lymphomas
• Can cause cardiomyopathy
• Myocyte damage
• Production of toxic
radicals
• Increase in oxidative
stress
• Lipid peroxidation
• Vacuolation
• Myocyte replacement
by fibrous tissue
Chemotherapy-Induced
Cardiomyopathy
• Symptoms
• palpitations, shortness of
breath, chest pain, fatigue
• Acute Cardiovascular
Complications
• Short-term
• Arrythmias
• Chronic Cardiotoxicity
• Clinical heart failure
• May be a link between acute and
chronic cardiotoxicity
Risk Factors
• Cumulative dose
• Age
• Other cardiotoxic chemotherapy
agents
• Radiation
• History of CVD
My Research
• Purpose is to identify most prevalent risk
factor
• Review charts of prior and current patients
of Dr. Barouch to study patients’ histories
• Be able to ascertain most common risk
factor
• Patients with that risk factor can then
consider their options
Conclusion
•Certain chemotherapy drugs,
such as anthracyclines, damage
myocardial function
•Cardiomyopathy can result
•Important to determine which
risk factors are most
detrimental
•Prevention medication and
screening can help reduce risk
of cardiomyopathy
Works Cited
Barouch, Lili. Personal interview. 23 Oct. 2013.
Gharib, M. I., and A. K. Burnett. "Chemotherapy-induced
Cardiotoxicity: Current Practice and Prospects of Prophylaxis."
European Journal of Heart Failure (2002).
Oxford Journals. Web.
19 Oct. 2013.
Hare, Joshua M. "The Etiologic Basis of Congestive Heart Failure."
Atlas of Heart Failure: Cardiac Function and Dysfunction. 3rd ed.
2002. Print.
Katz, Arnold M. "Molecular and Cellular Basis of Contraction." Atlas of
Heart Failure: Cardiac Function and Dysfunction. Ed. Wilson S.
Colucci. 3rd ed. 2002. Print.
Singal, Pawan K., and Natasha Iliskovic. "Doxorubicin-Induced
Cardiomyopathy." New England Journal of Medicine (1998). Google
Scholar. Web. 19 Oct. 2013.